FDA Staff Raises Concerns on Breast, Prostate Cancer Drug Applications

(MedPage Today) — For the first time since last July, the FDA’s Oncology Drug Advisory Committee (ODAC) will meet Thursday to evaluate two cancer drugs after FDA staff expressed concerns about the benefit-risk assessments, despite positive trials…